EU bars Chinese firms from most medical device tenders

The EU will block Chinese firms from most medical device tenders exceeding 5 million euros, impacting a market worth approximately 60 billion euros annually, due to concerns over reciprocal market access in China. This action, the first under the EU's International Procurement Instrument, aims to address what the EU views as unfair advantages for Chinese companies in their domestic market, potentially escalating trade tensions between the EU and China amidst existing disputes over electric vehicle tariffs and rare earth exports.

Analysis

The European Union has implemented its first significant measure under the 2022 International Procurement Instrument, barring Chinese companies from participating in EU public tenders for medical devices valued above five million euros each. This action impacts an estimated 60 billion euros ($68.9 billion) annually in tender value, representing approximately 60% of the total value of the EU's public medical device procurement market, which itself is 70% of the roughly 150 billion euro overall EU medical technology market in 2023. The European Commission justifies this exclusion by citing a lack of reciprocal market access for EU companies in China and evidence of Chinese practices that favor domestic devices and lead to abnormally low bids. Successful bids within these restricted tenders must now ensure that medical devices sourced from China constitute no more than 50% of the total, although an exemption applies if no alternative suppliers are available. This policy, covering items such as imaging equipment, artificial body parts, and medical clothing, is poised to exacerbate existing trade tensions between the EU and Beijing, already strained by disputes over electric vehicle tariffs, Chinese measures against EU brandy, and rare earth export curbs. While China's commerce ministry has labeled the EU's move as 'protectionist,' the Commission notes that China has not yet proposed corrective actions, though an agreement remains a possibility.

Key Decisions for Investors

• Investors should evaluate European medical device manufacturers, particularly those with substantial exposure to EU public tenders, as they may benefit from reduced competition from Chinese firms in high-value contracts.
• Caution is warranted for investments in Chinese medical device companies that have significant reliance on the EU public procurement market, given the new restrictions on tenders exceeding five million euros and the 50% cap on Chinese-sourced content.
• Monitor the escalating trade tensions between the EU and China, as this measure could prompt retaliatory actions or influence broader market sentiment and supply chain stability across various sectors beyond medical devices.
• Consider opportunities for companies, both within and outside the EU, that can offer alternative medical device supplies or components, as EU procurers will need to diversify sourcing to comply with the new content regulations.